Inclusion criteria:
The age of 18 to 75 years of both sexes is male and female
The level of patient's TSH when entering the study is between 0.5 and 4.5 Miu / l
At least six months, the patient's dose of levothyroxine has not changed
Exclusion criteria:
Patients with thyroid cancer, chronic gastrointestinal diseases, celiac disease, lactose intolerance, intestinal infections (Giardia lamblia), chronic lung, kidney and liver disease (cirrhosis), kidney stones, or history of kidney stones, CHF, vitamin B12 deficiency, pancreatic insufficiency As well as patients with jejunostyle or jejunoileal bypass, suffering from short-systolic syndrome or autoimmune gasteritis and H.Pylori infection
Pregnant, lactating and purpose to pregnancy women
Hormone-treated patients, such as taking contraceptives or estrogen and testosterone over the past three months
Patients treated with any of the following drugs or compounds: ferrous sulfate, calcium carbonate, colestipol, aluminum hydroxide, sucralfate, propranolol, laxatives, levostatin, solvate ester (sevelamer), cromium picolinate, bile acid sequestrants Gastric acid antacids, sucralfate, sodium polysterone sulfonate, cholesterol, dopamine analogues, steroids, somatostatin and also anticonvulsants, raloxifene, cimetidine, amiodarone, sertraline and activated charcoal.
Patients who have a change in their TSH for more than 1 unit in the first 8 weeks of their study or who have complications of vitamin C (severe nausea and vomiting or severe diarrhea)